Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence
Opioid neurotransmission mediates hedonic value of sweet tastants; their intake may be exaggerated by the consumption of exogenous opioids (e.g., opioid dependence). Sweet Taste Test (STT) is a validated quantitative instrument assessing taste perception and hedonic features of sugar (sucrose) using a randomized and double-blind administration at five different sucrose concentrations ranging from 0.05 to 0.83 M.
The STT and cue-induced craving procedure were administered to opioid-dependent patients (n = 15) before and 1 week after the injection of a long-acting depot naltrexone (XRNT) preparation.
Analyses of covariance, employing sucrose concentration and its perceived taste as covariates, showed that XRNT therapy significantly reduced the self-reported hedonic and motivational characteristics of sucrose. Greater reductions in both these characteristics were associated with more diminution in the cue-induced opioid craving.
Opioid antagonism in opioid-dependent subjects leads to a smaller sweet taste reward, which, in turn, may be proportional to decreased opioid craving. These pilot results support the heuristic value of the STT as a potential marker of the XRNT treatment response and call for further inquiry into potential clinical applications of the test.
KeywordsNaltrexone Glucose Sucrose Opioid Antagonist Reward Motivation Hedonic Sweet taste test Craving Incentive sensitization
- Elman I, Karlsgodt KH, Gastfriend DR, Chabris CF, Breiter HC (2002) Cocaine-primed craving and its relationship to depressive symptomatology in individuals with cocaine dependence. J Psychopharmacol 16(2):163–167Google Scholar
- First M (2002) Diagnostic and statistical manual of mental disorders. Text revision, 4th edn. American Psychiatric Association, WashingtonGoogle Scholar
- Grella CE, Lovinger K (2011) 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug and Alcohol Depend. doi:10.1016/j.drugalcdep.2011.04.004
- Lobmaier P, Kornor H, Kunoe N, Bjorndal A (2008) Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. CD006140Google Scholar
- Ward AS, Collins ED, Haney M, Foltin RW, Fischman MW (1999) Blockade of cocaine-induced increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of smoked cocaine in humans. Behav Pharmacol 10(5):523–529Google Scholar